Tags

Type your tag names separated by a space and hit enter

Frontrunners in the race to develop a SARS-CoV-2 vaccine.
Can J Microbiol. 2021 Mar; 67(3):189-212.CJ

Abstract

Numerous studies continue to be published on the COVID-19 pandemic that is being caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Given the rapidly evolving global response to SARS-CoV-2, here we primarily review the leading COVID-19 vaccine strategies that are currently in Phase III clinical trials. Nonreplicating viral vector strategies, inactivated virus, recombinant protein subunit vaccines, and nucleic acid vaccine platforms are all being pursued in an effort to combat the infection. Preclinical and clinal trial results of these efforts are examined as well as the characteristics of each vaccine strategy from the humoral and cellular immune responses they stimulate, effects of any adjuvants used, and the potential risks associated with immunization such as antibody-dependent enhancement. A number of promising advancements have been made toward the development of multiple vaccine candidates. Preliminary data now emerging from phase III clinical trials show encouraging results for the protective efficacy and safety of at least 3 frontrunning candidates. There is hope that one or more will emerge as potent weapons to protect against SARS-CoV-2.

Authors+Show Affiliations

Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada. Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada. Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada. Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33264067

Citation

Russell, Raquel L., et al. "Frontrunners in the Race to Develop a SARS-CoV-2 Vaccine." Canadian Journal of Microbiology, vol. 67, no. 3, 2021, pp. 189-212.
Russell RL, Pelka P, Mark BL. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Can J Microbiol. 2021;67(3):189-212.
Russell, R. L., Pelka, P., & Mark, B. L. (2021). Frontrunners in the race to develop a SARS-CoV-2 vaccine. Canadian Journal of Microbiology, 67(3), 189-212. https://doi.org/10.1139/cjm-2020-0465
Russell RL, Pelka P, Mark BL. Frontrunners in the Race to Develop a SARS-CoV-2 Vaccine. Can J Microbiol. 2021;67(3):189-212. PubMed PMID: 33264067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Frontrunners in the race to develop a SARS-CoV-2 vaccine. AU - Russell,Raquel L, AU - Pelka,Peter, AU - Mark,Brian L, Y1 - 2020/12/02/ PY - 2020/12/3/pubmed PY - 2021/3/2/medline PY - 2020/12/2/entrez KW - COVID-19 KW - SARS-CoV-2 KW - SRAS-CoV-2 KW - Severe Acute Respiratory Syndrome Coronavirus 2 KW - coronavirus 2 du syndrome respiratoire aigu sévère KW - développement de vaccins KW - vaccine development SP - 189 EP - 212 JF - Canadian journal of microbiology JO - Can J Microbiol VL - 67 IS - 3 N2 - Numerous studies continue to be published on the COVID-19 pandemic that is being caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Given the rapidly evolving global response to SARS-CoV-2, here we primarily review the leading COVID-19 vaccine strategies that are currently in Phase III clinical trials. Nonreplicating viral vector strategies, inactivated virus, recombinant protein subunit vaccines, and nucleic acid vaccine platforms are all being pursued in an effort to combat the infection. Preclinical and clinal trial results of these efforts are examined as well as the characteristics of each vaccine strategy from the humoral and cellular immune responses they stimulate, effects of any adjuvants used, and the potential risks associated with immunization such as antibody-dependent enhancement. A number of promising advancements have been made toward the development of multiple vaccine candidates. Preliminary data now emerging from phase III clinical trials show encouraging results for the protective efficacy and safety of at least 3 frontrunning candidates. There is hope that one or more will emerge as potent weapons to protect against SARS-CoV-2. SN - 1480-3275 UR - https://www.unboundmedicine.com/medline/citation/33264067/Frontrunners_in_the_race_to_develop_a_SARS_CoV_2_vaccine_ L2 - https://cdnsciencepub.com/doi/10.1139/cjm-2020-0465?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -